Business

Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6

Taysha Gene Therapies, Inc.January 6, 20265

Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

About this update from Taysha Gene Therapies, Inc.

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to

View stock analysis, news, and events for Taysha Gene Therapies, Inc.

More from Taysha Gene Therapies, Inc.

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 4, 2026

All Taysha Gene Therapies, Inc. news →